Can anyone really be surprised?  I remember Dr. Brawley talking to us young fellows about the hazards of prostate cancer screening as far back as 2003.  As I recall, he was even mad that there was a prostate cancer postage stamp! 

I recently had a health journalist interview me about the new guidelines for mammography under 50.

You may recall a storm of controversy was touched off in December 2009, when the US Preventive Services Task Force recommended that mammography begin at 50.  Sarah Palin went so far as to compare these recommendations to "death panels" under health care reform.  The controversy died down, and health care reform legislation was rewritten to ensure access to mammographic screening.

According to a report by the Reuters Roche Holding AG the world's largest maker of cancer drugs said that Avastin or bevacizumab which the company markets with Genentech Inc. met its prime endpoint in a phase III breast cancer trial when it was disclosed that Avastin is in fact effective for breast cancer sufferers as well. The drug is categorized as a "monoclonal antibody" and "anti-angiogenesis" and is the best-selling drug.

Psychological disorders are complex and the number of treatments available in the United States continues to grow but virtually all medications used to treat depression are metabolized by two enzymes in the liver: CYP2D6 and CYP2C19. Your genes are the main factor determining the level of these enzymes-if you have too much of the enzyme you process the medication too quickly too little of the enzyme and the medication builds up in your bloodstream potentially causing adverse reactions or side effects.

Sara Kenyon from the Reproductive Sciences section Cancer Studies and Molecular Medicine and the Health Sciences Department at the University Of Leicester authored two studies namely ORACLE I and ORACLE II with the help of other professors in an endeavor to evaluate the use of antibiotics in pregnant women with either preterm rupture of the membranes (ORACLE I study) or those with spontaneous preterm labour (ORACLE II study). The ORACLE Children Study was a long-term follow-up of these studies which was in two parts viz.

A new approach to protecting against HIV has shown early promise in laboratory testing. Preliminary SHIV challenge results on non-human primates which were previously vaccinated with a mucosal HIV-AIDS immunization have been released by the Mymetics Corporation. The effectiveness for the experiment was greater than the 60% industry standard which demarcates the levels at which a vaccine can be thought of as having viable potential. Mymetics Corporation intends to present the findings at the "Keystone Symposia" having conducted further research and analysis.

Preliminary SHIV challenge results on non-human primates which were previously vaccinated with a mucosal HIV-AIDS immunization have been released by the Mymetics Corporation. The effectiveness for the experiment was greater than the 60% industry standard which demarcates the levels at which a vaccine can be thought of as having viable potential. Mymetics Corporation intends to present the findings at the "Keystone Symposia" having conducted further research and analysis.

Preliminary SHIV challenge results on non-human primates which were previously vaccinated with a mucosal HIV-AIDS immunization have been released by the Mymetics Corporation. The effectiveness for the experiment was greater than the 60% industry standard which demarcates the levels at which a vaccine can be thought of as having viable potential. Mymetics Corporation intends to present the findings at the "Keystone Symposia" having conducted further research and analysis.

Specifically the alert focused on heparin and warfarin low molecular weight and low molecular weight enoxaparin.